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The Ras(17N) dominant negative antagonizes endogenous Ras function by forming stable, inactive complexes
with Ras guanine nucleotide exchange factors (GEFs; e.g., SOS1). We have used the growth-inhibitory
phenotype of Ras(17N) to characterize two aspects of Ras interaction with GEFs. First, we used a
nonprenylated version of Ras(17N), designated Ras(17N/186S), which no longer associates with the plasma
membrane and lacks the growth-inhibitory phenotype, to address the importance of Ras subceliular location
and posttranslational modification for its interaction with GEFs. We observed that addition of an N-terminal
myristylation signal to Ras(17N/186S) restored the growth-inhibitory activity of nonprenylated Ras(17N).
Thus, membrane association, rather than prenylation, is critical for Ras interaction with Ras GEFs. Second,
we used a biological selection approach to identify Ras residues which are critical for Ras(17N) growth
inhibition and hence for interaction with Ras GEFs. We identified mutations at residues 75, 76, and 78 that
abolished the growth-inhibitory activity of Ras(17N). Since GEF interaction is dispensable for oncogenic but
not normal Ras function, our demonstration that single-amino-acid substitutions at these three positions
impaired the transforming activity of normal but not oncogenic Ras provides further support for the role of
these residues in Ras-GEF interactions. Finally, Ras(WT) proteins with mutations at these residues were no
longer activated by mammalian SOS1. Altogether, these results suggest that the Ras intracellular location and
Ras residues 75 to 78 are critical for Ras-GEF interaction.
The four human Ras proteins (H-, N-, K4A-, and K4B-
Ras) are members of a large superfamily of small guanine
nucleotide-binding proteins that function as molecular
switches to regulate signal transduction pathways important
for modulating cell growth and differentiation (1, 3). Ras
protein function is controlled by a GDP-GTP cycle that is
regulated by at least two distinct classes of regulatory
proteins. First, GTPase-activating proteins (p120 GAP and
neurofibromin/NF1 GAP) recognize the active, GTP-bound
protein and stimulate the intrinsic GTPase activity of Ras
proteins to form the inactive, GDP-bound protein (2). Sec-
ond, guanine nucleotide exchange factors (GEFs) promote
the dissociation of bound nucleotide to promote the forma-
tion of the active, GTP-bound state (13). Several Ras GEFs
have recently been molecularly cloned and characterized.
These include mammalian homologs of the yeast CDC25 and
SDC25 (designated GNRF, CDC25Mm, or mCDC25) (24, 35,
41) and the Drosophila SOS (SOS1 and SOS2) (4) proteins.
smg GDS represents a fourth Ras GEF (15), whereas the
Vav protein, which shares homology with the Dbl family of
putative GEFs for the Rho family of Ras-related proteins,
has also been shown to stimulate Ras GDP-GTP exchange
(17).
Although the precise role of each GEF regulatory protein
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remains to be established, the observation that a putative
GEF-complexing Ras mutant, Ras(17N), is a potent inhibi-
tor of cell proliferation supports a critical role for GEF in
Ras function (14, 37). Present evidence suggests that the
growth-inhibitory activity of the constitutively GDP-bound
Ras(17N) protein is a consequence of its formation of an
inactive complex with Ras GEFs (30), thus preventing the
activation of endogenous Ras. Presently, there is no direct
evidence that Ras(17N) growth inhibition is due to this
mechanism. However, support for this mechanism is pro-
vided by the demonstration that overexpression of the yeast
SDC25 protein, which functions as a Ras GEF (31), reverses
Ras(17N) growth inhibition in NIH 3T3 cells (33).
Although guanine nucleotide binding is essential for Ras
function, Ras biological activity is also critically dependent
on its localization to the inner face of the plasma membrane
(11, 22). Ras membrane association is triggered by a series of
three closely linked posttranslational modifications (preny-
lation, proteolysis, and carboxylmethylation) that are sig-
naled by the C-terminal CXXX (where C is cysteine and X is
any amino acid) sequence, which is present on all Ras
proteins. Mutation of the cysteine residue of the CXXX
motif prevents prenylation, and such mutant proteins are no
longer associated with the plasma membrane, are cytosolic,
and are completely nontransforming. However, although it
is clear that prenylation and membrane association are
essential for Ras function, their precise contributions to Ras
function remain to be established.
Ras function may be dependent on prenylation to promote
the interaction of Ras proteins with regulatory proteins such
1113
Vol. 14, No. 2
1114 QUILLIAM ET AL.
as GAPs and GEFs that control its GDP-GTP cycle or with
upstream (e.g., receptor tyrosine kinases) or downstream
(e.g., serine/threonine kinases) components required for
completion of the Ras signaling pathway (1). This require-
ment may reflect the possibility that such proteins recognize
only the prenylated form of Ras. For example, smg GDS
stimulates GDP-GTP exchange on only the prenylated forms
of K-Ras4B and RhoA (26). Additionally, Ras prenylation
was found to be required for Ras activation of mitogen-
activated protein kinase in a cell-free assay (19).
Alternatively, the membrane location produced upon pre-
nylation may be required for Ras interaction with other
proteins. This possibility is supported by the observation
that the fatty acid myristate can replace prenylation to
promote Ras membrane association and transforming activ-
ity (7). In addition, although Ras GAPs can readily stimulate
the GTPase activity of nonprenylated Ras proteins, plasma
membrane targeting greatly potentiates the negative regula-
tory activity of both p120 GAP and NF1 GAP (10, 18). Thus,
it may be the subcellular location, rather than prenylation
itself, that is required for Ras interaction with other proteins.
In the studies presented here, we have used the Ras(17N)
dominant inhibitory mutant to address the role of Ras GEFs
in Ras function. Our results suggest that membrane associ-
ation, rather than prenylation per se, is critical for Ras-GEF
interactions and that the Ras domain containing residues 75
to 78 may be essential for GEF activation of normal Ras
biological activity but is dispensable for the transforming
activity of oncogenic Ras.
MATERIALS AND METHODS
Molecular constructs. The Ras(17N/186S) mutant contains
a cysteine-to-serine substitution of the cysteine residue in
the C-terminal CXXX prenylation signal sequence present in
all Ras proteins (11, 22). This Ras(17N) variant no longer
undergoes prenylation, is not membrane associated, and
lacks the growth-inhibitory activity of Ras(17N) (14). We
have previously shown that addition of an N-terminal myris-
tylation signal sequence to the N terminus of Ras proteins
can substitute for prenylation to restore membrane associa-
tion and transforming activity (7). To generate a myristylated
form of Ras(17N/186S), a 0.7-kb HindIII-BamHI fragment
that encodes residues 6 to 189 of the Ras(17N/186S) mutant
protein (provided by Larry Feig) was ligated with a 0.4-kb
BglII-HindIII fragment that encodes an 11-residue N-termi-
nal myristylation signal sequence (derived from the rat
leukemia virus Gag protein) and the first five residues of
human H-Ras and then introduced into the BamHI site of the
pZIP-NeoSV(x)1 retrovirus vector plasmid [designated Myr-
ras(17N/186S)] (7). pZIP retrovirus constructs of ras(61L),
ras(17N), ras(17N/186S), and Myr-ras(186S) were con-
structed as described previously (7).
An expression construct encoding the catalytic domains of
mouse SOS1 (provided by D. Broek) was generated by PCR
amplification of cDNA sequences of mouse SOS1 with a 5'
synthetic oligonucleotide that introduced an EcoRI site and
initiating ATG codon and a 3' oligonucleotide that intro-
duced a stop codon followed by an EcoRI restriction site.
The PCR-generated fragment encoding human mouse
mSOS1 residues 559 to 1071 was then introduced into the
unique EcoRI site of a modified version of pZIP-NeoSV(x)1
(pZBR) and was designated pZIP-SOS(c) (30a).
In vitro random mutagenesis. In vitro random mutagenesis
of pZIP-Myr-ras(17N/186S) plasmid DNA was done as de-
scribed previously (14). Briefly, 30 p,g of plasmid DNA in 30
,ul of H20 was mixed with 150 ,ul of ethylene glycol and
heated to 70°C for 5 min. After a 27-pul aliquot was removed
for the nonmutated control, 16 ,ul of hydroxylamine solution
(0.5 M in 0.2 M sodium PPi) was added to the remaining
DNA solution. Incubation was continued at 70°C for 60 min,
with 30-,ul aliquots being removed at 10-min intervals, and
the reaction was stopped by the addition of 80 p,l of ice-cold
stop solution (0.6 M Tris-HCl [pH 8.0], 1.0 M NaCl, 20%
acetone). Each DNA fraction was then centrifuged through
1.0-ml Sephadex G-100 columns to remove the residual
hydroxylamine. The degree of mutagenesis was quantitated
by determining the reduction of ampicillin resistance of the
treated DNA after transformation into Escherichia coli
HB101. DNA aliquots representing 30 to 40% reduction in
ampicillin resistance (corresponding to approximately one
mutation per molecule) were then used for transfection into
NIH 3T3 cells as described below.
Cell culture and transfection assays. NIH 3T3 cells were
grown in Dulbecco's modified Eagle's medium supple-
mented with 10% calf serum, and DNA transfections by the
calcium phosphate precipitation technique were done as
described previously (7), with each dish containing 100 to
1,000 ng of pZIP-rasH DNA encoding each mutant Ras
protein. Transfected cells were maintained in growth me-
dium, and transformed foci were quantitated after 14 days.
Transfected NIH 3T3 cells were also selected in growth
medium containing 400 jig of G418 (Geneticin; GIBCO BRL)
per ml to establish cell lines expressing each mutant Ras
protein or to quantitate cell growth inhibition.
Subcellular localization and analysis of Ras expression.
G418-selected NIH 3T3 cells expressing each mutant protein
were labeled overnight in growth medium supplemented
with 200 ,uCi of [3 S]methionine/cysteine (Tran35S-label;
ICN) per ml. For fractionation analysis, labeled cells were
separated into crude membrane (P100)- and cytosol (S100)-
containing fractions by centrifugation (100,000 x g for 30
min) as described previously (7). Ras proteins were immu-
noprecipitated from each fraction with the rat Y13-259 and
mouse 146-3E4 (specific for H-Ras; Quality Biotech, Cam-
den, N.J.) anti-Ras monoclonal antibodies resolved by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis,
and subjected to fluorographic analysis as described previ-
ously (7). In vivo guanine nucleotide association analysis
was done essentially as described previously (7). Briefly,
transfected NIH 3T3 cells expressing each of the different
mutant proteins were metabolically labeled overnight with
200 ,uCi of 32p; (Dupont NEN) per ml. The labeled cells were
first lysed with 1% Nonidet P-40 detergent buffer and then
subjected to immunoprecipitation with Y13-259. The bound
guanine nucleotides were released from the immunoprecip-
itated Ras proteins and separated by thin-layer chromatog-
raphy on PEI cellulose plates, and the percentage of GTP
bound was quantitated by AMBIS beta scanning.
Transcriptional activation CAT assays. Transcriptional ac-
tivation of expression from a promoter which contains
Ras-responsive elements (Ets-1 and AP-1 binding motifs)
was done essentially as described previously (10). Briefly,
NIH 3T3 cells were transfected with 1 ,ug of the pB4X-CAT
chloramphenicol acetyltransferase (CAT) reporter plasmid
(provided by B. Wasylyk) (8) together with 2 ,g of each
pZIP-ras mutant. The ability of Ras GEFs to stimulate the
ability of normal Ras to activate transcription from pB4X-
CAT was determined by cotransfection with 100 ng of
pZIP-SOS(c). To evaluate the ability of Ras(17N) to compete
with mouse SOS1, cultures were cotransfected with 2 ,ug of
pZIP-rasH(WT) and 0.1 p,g of pZIP-SOS(c) plasmid DNAs
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together with 1.0 p,g of pZIP-Ras(17N). All transfections
were performed in duplicate in 60-mm dishes. The cells were
harvested after 48 h and lysed in 100 pl of 250 mM Tris-HCl
(pH 7.8) by three cycles of freeze-thawing. Lysates were
clarified by microcentrifugation, with the resulting superna-
tant heated to 62°C to inactivate any endogenous acyltrans-
ferase activity, and then subjected to a second clarification
step. A 30-pl aliquot of each supernatant was then assayed
for CAT activity by incubation with 0.1 p,Ci of [14C]chloram-
phenicol (NEN) and 0.34 mM acetyl coenzyme A in 250 mM
Tris-HCl (pH 7.8) in a final reaction volume of 138 pl. After
45 min the reaction was halted by extraction with 500 ,ul of
ethyl acetate and evaporated under vacuum, and the result-
ing pellet was dissolved in 10 pl of ethyl acetate and
subjected to thin-layer chromatography in 5% methanol-
95% chloroform. Assays were quantitated by using an
AMBIS beta scanner.
RESULTS
Membrane association, rather than prenylation, is required
for 17N growth inhibition. Previous studies have established
that isoprenylation and membrane association are required
for the growth-inhibitory activity of Ras(17N) (14). To de-
termine whether Ras(17N) function is dependent on isopre-
nylation or membrane association, we generated a nonpre-
nylated form of Ras(17N) that was targeted to membranes
via myristylation. We have previously shown that addition
of an 11-amino-acid myristylation signal sequence to onco-
genic Ras will substitute for isoprenylation and restore Ras
transforming activity (7). Therefore, we introduced this
N-terminal myristylation signal onto the N terminus of a
cytosolic form of Ras(17N) [H-Ras(17N/186S)] to determine
whether myristate addition could replace isoprenylation to
restore the growth-inhibitory phenotype.
The growth-inhibitory activity of myristylated, nonpreny-
lated Ras(17N) [designated Myr-Ras(17N/186S)] was then
compared with that of both prenylated and nonprenylated
forms of Ras(17N). Although cultures transfected with 500
ng of pZIP-ras(WT7) plasmid DNA and subjected to selection
in G418-containing growth medium exhibited the appearance
of a near-confluent dish (>500 colonies) of drug-resistant
colonies, cultures transfected with pZIP-ras(17N) exhibited
a much reduced concentration of G418-resistant colonies
(Fig. 1). As described previously (14), the nonprenylated,
cytosolic version of Ras(17N) [Ras(17N/186S)] lacked
growth-inhibitory activity and displayed a greatly enhanced
concentration of G418-resistant colonies. However, the ad-
dition of an N-terminal myristylation signal sequence to this
mutant [Myr-Ras(17N/186S)] restored potent growth-inhibi-
tory activity (Fig. 1). Furthermore, since we observed fewer
G418-resistant colonies with the myristylated than the pre-
nylated form of 17N, the growth-inhibitory activity of Myr-
Ras(17N/186S) is apparently greater than that of the preny-
lated Ras(17N) protein. Thus, the membrane association
triggered by myristate can promote a sufficiently proper
location of Ras(17N) to allow expression of its growth-
inhibitory phenotype. These results suggest that membrane
association, rather than prenylation, is required for GEF
recognition of Ras proteins.
Isolation of Ras(17N) mutants which lack the growth-
inhibitory phenotype. Although it is believed that Ras(17N)
growth inhibition is a consequence of its formation of an
inactive complex with Ras GEFs, thereby preventing GEF
activation of endogenous Ras activity (14, 30), there is no
direct evidence for this model. To provide a better under-
Rasl7N/186S Myr-Rasl7N/186S
FIG. 1. Myristylation restores the growth-inhibitory activity of a
nonprenylated, cytosolic version of Ras(17N) [Ras(17N/186S)]. NIH
3T3 cells were transfected with 500 ng of pZIP-ras constructs
encoding Ras(WT), Ras(17N), Ras(17N/186S), and Myr-Ras(17N/
186S) and selected in G418-containing growth medium. After 14
days, the drug-resistant colonies were visualized by staining with
crystal violet.
standing of the biochemical mechanism of Ras(17N) growth
inhibition and to identify domains of Ras important for
Ras-GEF interaction, we have used a random-mutagenesis
method to identify second-site mutations that abolish the
growth-inhibitory phenotype of Ras(17N). Since we ob-
served that the myristylated form of Ras(17N) [Myr-
Ras(17N/186S)] displayed stronger growth-inhibitory activ-
ity than did the prenylated version [Ras(17N)], we used a
retrovirus construct [pZIP-Myr-ras(17N/186S)] encoding
this protein for the random-mutagenesis studies.
pZIP-Myr-ras(17N/186S) plasmid DNA was treated with
hydroxylamine to introduce random base pair substitutions
(G-to-A missense mutations) by using previously described
methods (14). The hydroxylamine-treated DNA was then
transfected into NIH 3T3 cells, and G418-resistant colonies
were isolated. Since stable expression of Ras(17N) is not
tolerated, the transfection of control, untreated pZIP-Myr-
ras(17N/186S) plasmid DNA typically resulted in the isola-
tion of only rare G418-resistant colonies (less than 1 colony
per 100-mm dish) (Fig. 1). In contrast, occasional G418-
resistant colonies were observed with the hydroxylamine-
treated DNA. Altogether, 16 G418-resistant colonies of
proliferating cells were observed in three 100-mm dishes.
The 16 individual colonies that arose from the hydroxyl-
amine-treated DNAs were then isolated to establish clonal
cell lines for further analysis.
We anticipated that a variety of mutations in Myr-
Ras(17N/186S) may account for the outgrowth of G418-
resistant cells. For example, in addition to mutations that
may prevent Ras-GEF interaction, the loss of the growth-
inhibitory activity of Ras(17N) may be a consequence of
mutations that introduce premature stop codons that then
encode truncated, nonfunctional proteins. Alternatively,
missense mutations that cause protein instability may have
been introduced. To determine whether these two classes of
mutations were present, the cells representing the 16 indi-
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TABLE 1. Mutations that abolish the growth-inhibitory
phenotype of Ras(17N)
Amino acid at Ras residue:
Protein
70 71 72 73 74 75 76 77 78 79 80
Ras mutants






H-Ras Q Y M R T G E G F L C
N-Ras
K-Ras
Rapla,b L - K N Q - - A L
R-ras A H - - - L
TC21..- L
Ral N F - S
Rabla S Y -G A H -I I V
Rab3a A Y -G A M --I L
Racl,2 S P Q - D V F L I
RhoA,B,C S P D- D V I L M-
a - indicates identity with H-Ras at the indicated residue.
vidual G418-resistant colonies were used for Western blot
analysis to assay for expression of the 22-kDa Myr-Ras
protein. Of the 16 cell lines, only 2 (designated clones 4-5 and
6-6) expressed a detectable 22-kDa Myr-Ras protein (data
not shown). Thus, the remaining 14 drug-resistant cell lines
may express either truncated or unstable Myr-Ras proteins.
Another possible mutation that would abolish Myr-
Ras(17N/186S) growth inhibition would be the loss of the
glycine residue, which is the site of myristate addition, in the
N-terminal myristylation sequence. However, fractionation
analysis of the 4-5 and 6-6 cells indicated that both of these
cell lines expressed a membrane-associated form of p22
Myr-Ras (data not shown), suggesting that these two Myr-
Ras variants still undergo myristylation. Therefore, the
apparent loss of growth-inhibitory activity of these two
Myr-Ras variants may be the consequence of mutations that
either removed the 17N mutation or contained mutations at
sequences that prevented their interaction with Ras GEFs.
Cell lines 4-5 and 6-6 were used for further analysis to
determine the nature of the mutation(s) which allowed stable
expression of Myr-Ras(17N). To address this directly,
genomic DNA was isolated from cell lines 4-5 and 6-6,
subjected to PCR amplification with primers corresponding
to the 5' and 3' sequences of the Myr-ras(17N/186S) cDNA,
subcloned into the M13mp18 phage construct, and analyzed
by dideoxy sequencing. Sequences derived from both 4-5
and 6-6 retained the coding sequence for asparagine at codon
17. Instead, the sequence derived from 4-5 cells contained a
single-base substitution at codon 78 of the H-Ras coding
sequence which results in a Phe (TIC)-to-Leu (CTC) substi-
tution, whereas the sequence derived from 6-6 cells con-
tained two base substitutions at codons 75 and 76 which
result in a double substitution of Gly (GGG) to Glu (GAG) at
position 75 and of Glu (GQAGj) to Lys (AAA) at position 76
(Table 1). These results suggest that the Ras sequence
corresponding to residues 75 to 78 is essential for Ras(17N)
growth inhibition and may therefore be important for inter-
action with Ras GEFs.
Mutations at residues 75 to 78 abolish 17N growth inhibition
and reduce normal, but not oncogenic, Ras transforming
potential. To characterize the role of residues 75 to 78 in Ras
function, we first introduced the same single-amino-acid
substitutions into this region of the normal, prenylated
version of the Ras(17N) mutant protein. As we had observed
with the Myr-Ras(17N/186S) protein, these substitutions
also abolished the growth-inhibitory activity of the preny-
lated version of Ras(17N) (Fig. 2A). Whereas cultures trans-
fected with 100 ng of pZIP-ras(17N) displayed very few
G418-resistant colonies [which typically express no, or very
low levels of, Ras(17N) (14)], cultures transfected with
versions of Ras(17N) containing amino acid substitutions at
residues 75, 76, and 78 all showed the appearance of drug-
resistant colonies that were comparable in number to those
observed with cells transfected with Ras(WT). Interestingly,
although the 6-6 Myr-Ras(17N) revertant contained two
amino acid substitutions, either substitution alone was suf-
ficient to reverse Ras(17N) growth inhibition. Finally, the
expression of Ras(17N) proteins with mutations at residues
75 to 78 were readily detectable in stably transfected NIH
3T3 cells, indicating that these mutations did not reverse
Ras(17N) growth inhibition by merely causing protein insta-
bility (Fig. 2B). Thus, the ability of mutations at residues 75
to 78 to abolish the growth-inhibitory phenotype of preny-
lated Ras(17N) defines a Ras domain which is critical for the
dominant negative nature of this mutant and suggests that
this region may be important for interaction with Ras GEF.
Since oncogenic forms of Ras are no longer responsive to
GAP-stimulated GTP hydrolysis, these proteins are consti-
tutively GTP bound and are presumably independent ofGEF
stimulation for their transforming activity. Consistent with
this possibility, genetic studies with Saccharomyces cerevi-
siae have shown that activated forms of Ras can overcome
the loss of yeast RAS GEF (CDC25) function (5) and that
Ras(17N) growth inhibition can be reversed by coexpression
of oncogenic Ras (14). Consequently, if residues 75 to 78 are
important for interaction with a Ras GEF, we would expect
this domain to be critical for the activity of normal, but not
oncogenic, Ras proteins. To address this possibility, we
introduced either single or double mutations at residues 75 to
78 into both normal (WT) and oncogenic (12R) Ras se-
quences and determined their transforming activities in
transfected NIH 3T3 cells. The potent focus-forming activity
of Ras(12R) was not abolished by the individual substitutions
at residues 75 to 78 (Table 2), and cells expressing these
mutants also exhibited the same transformed morphology as
cells expressing nonmutated Ras(12R) (Fig. 3). In contrast,
when the individual mutations were introduced into residue
75, 76, or 78 of normal Ras(WT) protein, transforming
activity was found to be significantly reduced (Table 2).
Thus, this demonstration that Ras residues 75 to 78 are
dispensable for oncogenic but not normal Ras-transforming
activity is consistent with their possible involvement in GEF
interactions. Furthermore, since oncogenic Ras transform-
ing activity and preferential binding to GTP (Fig. 2C) are
retained, mutations at residues 75 to 78 do not merely
reverse Ras(17N) activity by abolishing Ras guanine nucle-
otide binding. The reversal of Ras(17N) growth inhibition by
mutations at residues 75, 76, and 78 was not due to these
mutants producing transforming proteins since cells overex-
pressing these proteins had normal morphology and did not
generate transforming foci. Finally, since the double
75E,76K mutant reduced the transforming activity of
Ras(12R) without significantly reducing the level of protein
expression (Fig. 2B) or Ras(12R) GTP/GDP ratio (Fig. 2C), it
is possible that this mutant has a more drastic effect on Ras
conformation that also perturbs effector function.
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TABLE 2. Transforming activity of mutants of Ras(WT) and
Ras(12R) with mutations at residues 75 to 78a
No. of foci/Lg of DNA in:
Mutant
Expt 1 Expt 2 Expt 3
WT 78 52 29
75E <1 7 6
76K NDb 12 <1
78L 8 16 11
75E,76K <1 6 <1
12R 4,410 3,115 3,100
12R/75E 1,565 2,400 3,060
12R/76K ND 2,775 3,450
12R/78L 3,440 3,310 3,150
12R/75E,76K 65 590 665
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FIG. 2. Mutations at residues 75 to 78 reverse the Ras(
growth-inhibitory phenotype in NIH 3T3 cells. (A) Grow
G418-resistant cells. NIH 3T3 cells were transfected with 500
pZIP-ras constructs encoding Ras(WT), Ras(17N), Ras(17N/
Ras(17N/76K), Ras(17N/78L), and Ras(17N/75E,76K). G418-
tant colonies were visualized by staining with crystal violel
Expression of Ras proteins with mutations at residues 75
following isolation of stably transfected cells. Transfected cells
selected in G418-containing growth medium, metabolically la
with [35S]methionine-[35S]cysteine, and immunoprecipitated
146-3E4 anti-H-Ras monoclonal antibody. Ras proteins wer
tected by SDS-PAGE and fluorography. All proteins were re
detected, indicating that mutating residues 75 to 78 did not (
a NIH 3T3 cells were transfected with 1 i'g (experiments 1 and 2) or 2 p.g
(experiment 3) of pZIP-ras(WT) or with 20 ng of pZIP-ras(12R) constructs per
60-mm dish and incubated in growth medium for 14 days prior to quantitation
of transformed foci. Each experiment was performed in quadruplicate.
b ND, not done.
Mutations at residues 75 to 78 perturb Ras interaction with
GEF. The consequences of substitutions at residues 75 to 78
on the biological activities of Ras(WT), Ras(12R), and
Ras(17N) suggest that this domain is important for interac-
tion with a Ras GEF. To address this possibility directly, we
used transient-transfection transcription assays to determine
whether the catalytic domain of mouse SOS1 could still
stimulate the activities of Ras(WVT) mutant proteins with
mutations at residues 75 to 78. For these assays, we used the
ability of Ras GEFs and normal Ras to synergistically
stimulate transcriptional activation from a CAT reporter
construct (pB4X-CAT) which contains Ras-responsive se-
quence elements (the Ets-1 and AP-1 DNA-binding motifs
from the polyoma virus enhancer) in its promoter sequence
(10, 33). Although oncogenic Ras proteins can efficiently
(10- to 20-fold) activate transcription from pB4X-CAT (10),
normal Ras proteins display only weak stimulation of tran-
scription. However, cotransfection with pZIP-SOS1(c) can
stimulate (approximately threefold) the activity of normal
Ras(WT) protein in this assay (Fig. 4). In contrast, Ras(WT)
proteins with mutations at residue 75, 76, or 78 were found to
be significantly impaired in their ability to be transcription-
ally activated by SOS1. A similar loss of responsiveness was
also observed when these mutant proteins were coexpressed
with constructs encoding the catalytic domains of mamma-
lian CDC25 or yeast SDC25 Ras GEFs (data not shown).
Thus, residues 75, 76, and 78 are important for proper
interaction with these Ras GEFs.
Mammalian SOS1 can overcome the inhibitory activity of
Ras(17N). Although recent studies have shown that yeast
100 SDC25 is a Ras GEF and that overexpression of SDC25 can
overcome the inhibitory activity of Ras(17N) (33), it is
(17N) presently not known which mammalian GEF(s) is the target
th of for Ras(17N) inhibition. Therefore, we used SOS1-induced










significant protein instability. (C) In vivo guanine nucleotide asso-
ciation analysis. NIH 3T3 cells expressing each of the different
mutant proteins were metabolically labeled overnight with 32p; and
then solubilized in detergent buffer. Labeled guanine nucleotides
bound to Ras proteins were immunoprecipitated and analyzed by
thin-layer chromatography.
A
Ras WT Ras 17N Ras 17N/75E
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Ras Wr Ras 12R Ras 12R/75E
Ras 12R/76K Ras 12R/78L Ras 12R/75E,76K
FIG. 3. Transformed morphology of NIH 3T3 cells stably expressing oncogenic Ras(12R) proteins with mutations at residues 75 to 78.
NIH 3T3 cells were transfected with 20 ng of pZIP constructs encoding each Ras mutant, and transfected cells were selected in
G418-containing growth medium.
mid to address the functional relationship between Ras(17N)
and the catalytic domain of mouse SOS1. We observed that
Ras(17N) completely blocked the ability of the catalytic
domain of SOS1 and Ras(WT) to stimulate transcription
activation from this Ras-responsive reporter (Fig. 5). How-
ever, cotransfection with an additional 25-fold excess of
pZIP-SOS1(c) plasmid DNA was found to reverse this
inhibition. Consequently, these results suggest that SOS1 is
at least one of the GEFs which are inactivated by Ras(17N).
DISCUSSION
The Ras(17N) mutant protein is a potent inhibitor of cell
proliferation and has been used widely as a dominant nega-
tive inhibitor of endogenous Ras function (14, 37). Ras(17N)
preferentially binds to GDP and consequently is believed to
form an inactive complex with Ras GEFs (14). Consistent
with this proposal, overexpression of a yeast Ras GEF
(SDC25) reverses Ras(17N) growth inhibition (33). Similarly,
overexpression of yeast CDC25 overcomes the inhibitory
activity of an analogous dominant negative mutant of yeast
RAS2(15A) (30). In this study, we have used Ras(17N) to
evaluate the role of Ras GEFs in regulating the activities of
normal and oncogenic Ras proteins and to identify Ras
residues which are important for this regulation.
The loss of growth inhibition observed with a CXXX
variant of Ras(17N), Ras(17N/186S), which is no longer
prenylated by the isoprenoid farnesyl or associated with the
plasma membrane (14), suggests that Ras interaction with
GEF is dependent on protein prenylation or, alternatively,
on localization of Ras proteins to the plasma membrane. Our
observation that the fatty acid myristate can restore the
growth-inhibitory activity of the nonprenylated Ras(17N)
mutant suggests that plasma membrane localization, rather
than prenylation, is required for a functional Ras-GEF
interaction. A membrane requirement for Ras interaction
with GEFs is unexpected since the mammalian SOS and
CDC25 homologs are active on unprocessed Ras proteins
and are present in the cytosol at significant levels (6, 35).
Thus, it would be expected that a cytosolic form of Ras(17N)
should still form a complex with GEF and would still be
growth inhibitory. However, since translocation of SOS to
the plasma membrane via the Grb2 adaptor protein is re-
quired for activation of Ras GDP-GTP exchange (6, 9, 12, 16,
21, 28, 32, 36), it may be that only membrane-associated
forms of GEFs are capable of efficiently interacting with
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pZIP Ras(WT) Ras(75E) Ras(76K) Res(78L)
FIG. 4. Mutation of Ras residues 75, 76, and 78 blocks SOS1-
stimulated transcriptional activation from Ras-responsive elements
in the pB4X-CAT reporter construct. NIH 3T3 cells were cotrans-
fected with 1 ,ug of the indicated pZIP-ras mutant alone or together
with 100 ng of pZIP-SOS(c) (catalytic domain of mouse SOS1) plus
1 Fg of the pB4X-CAT reporter construct. Whereas Ras(WT)
showed a threefold stimulation when coexpressed with SOS(c), the
75E, 76K, and 78L mutants were poorly responsive to SOS1
stimulation, suggesting that this region is critical for GEF-mediated
activation of Ras. Results are representative of at least three
independent experiments, which were performed in duplicate.
Ras. This may reflect the possibility that the membrane-
associated forms of GEFs are differentially modified (e.g.,
by phosphorylation) to facilitate their interaction with mem-
brane-bound Ras proteins in vivo.
Although the Ras sequences responsible for Ras interac-
tion with negative regulatory GTPase-activating proteins has
been established (primarily residues 32 to 40), the Ras
domains important for GEF interactions are presently poorly
defined (23, 29). In this study, we have used a random-
mutagenesis method to introduce second-site mutations that
abolish the growth-inhibitory phenotype of Ras(17N) as one
approach to identify Ras residues that may be important for






Ras(WT) 2.0 Lg - + + + +
SOS(c) 0.1g - - + + + -
SOS(c) 2.5 gg - - - - - +
Ras(17N) 1.Oig- + +
FIG. 5. Ras(17N) inhibition of SOS1 activity is overcome by
overexpression of SOS1. Although neither Ras(WT) nor SOS1(c)
alone showed significant stimulation of transcription from pB4X-
CAT, cotransfection of Ras(WT) and SOS(c) resulted in eightfold
stimulation. Ras(17N) efficiently blocked this activation. However,
excess SOS(c) was able to reverse this inhibitory activity.
normal Ras proteins can overcome a CDC25 defect in S.
cerevisiae (5), we also expected that such mutations would
impair the transforming activity of normal but not oncogenic
Ras proteins. We observed that single-amino-acid substitu-
tions of residue 75, 76, or 78 completely abolished the
growth-inhibitory activity of Ras(17N) and decreased the
transforming activity of normal but not oncogenic Ras.
Furthermore, Ras(WT) proteins with substitutions at these
residues were impaired in their ability to be activated by the
catalytic domain of SOS1. Taken together, these observa-
tions suggest that these mutations have impaired the ability
of Ras to associate with GEFs and that residues 75 to 78 are
important for a functional Ras-GEF interaction. Although it
is possible that the mutations at residues 75 to 78 merely
reversed the guanine nucleotide-binding defect caused by
the S17N mutation, our observation of unchanged levels of
GTP (-90%) complexed to Ras(12R) proteins containing
mutations at these positions is inconsistent with this possi-
bility.
Our observation that residues 75 to 78 are important for
Ras-GEF interaction is similar to results described by Ver-
rotti et al. (40), who determined that yeast RAS2 residues 80
and 81 (corresponding to human Ras residues 73 and 74)
were important for stimulation of GDP-GTP exchange by
SDC25. They observed that amino acid substitutions at these
two residues impaired the function of wild-type RAS2 but
not G19V mutants of RAS2. Consequently, taken together
with our results, residues 73 to 78 may represent a Ras
domain which is essential for GEF activation of Ras GDP-
GTP exchange. Whether mutations at these residues perturb
both stimulation and binding or merely perturb stimulation is
presently not known. We are currently assessing the ability
of Ras proteins with mutations at positions 75 to 78 to
associate with Ras GEFs.
In contrast to our observations, two recent site-specific
mutagenesis studies have implicated other Ras residues
which may be important for Ras-GEF interaction. First,
Mistou et al. (25) determined that single-amino-acid substi-
tutions in loops L2 (T35A, D38A, and D38E) and LA (Q61H,
Q61L, E62H, and E63H) all strongly impaired stimulation,
but not binding, by SDC25. These residues are in the two
regions, designated switch I (residues 32 to 38) and II
(residues 60 to 76), whose conformations differ in the GDP-
and GTP-bound states of Ras proteins and which are also
involved in GAP binding and stimulation. Second, Segal et
al. observed that deletion of H-Ras residues 97 to 105, which
are dispensable for Ras transforming activity, impaired Ras
GEF (yeast and mouse CDC25, yeast SDC25) activation of
the ability of Ras to stimulate yeast adenylate cyclase
activity (34). The consequence of this deletion on GEF
binding was not determined. Although it is possible that the
different observations made in these studies merely reflect
the use of different assays for Ras-GEF interaction, it is also
likely that, whereas some Ras residues will be important for
GEF binding, others will be required for GEF stimulation.
How might residues 75 to 78 affect the interaction of Ras
with GEF? One logical possibility is that these residues
directly associate with GEFs (Fig. 6). Alternatively, they
may critically influence the conformational distinction be-
tween the GDP- and GTP-bound forms of Ras that allows
preferential recognition of Ras-GDP by GEFs. This second
possibility is supported by the observation that yeast CDC25
binds preferentially to the GDP-bound form of RAS2 and
that a conformational change to the GTP-bound state abol-
ishes CDC25 binding (27). As mentioned above, the switch I
and switch II domains that distinguish the GDP- and GTP-
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FIG. 6. Location of Ras residues 75, 76, and 78. Ras residue 75
may represent a critical position for the conformational switch
between Ras-GDP and Ras-GTP. Residue 76 is located in a loop
which is exposed at the surface of the Ras protein and may be
involved in interaction with Ras GEFs. The effects of a substitution
at residue 78 may be due to perturbation of the orientation or
flexibility of residues 75 and 76.
complexed forms of Ras have been defined by x-ray struc-
tural analyses (42). The backbone flexibility of residues 75
and 77 has been speculated to be important for the confor-
mational change between the biologically active Ras-GTP
and inactive Ras-GDP states (20). Furthermore, Kavounis et
al. (20) reported that a G82S (residue 75 in human Ras)
mutation in yeast RAS2 protein weakened interactions with
the nonhydrolyzable GTP analog Gpp(NH)p (20). They
speculated that this replacement might hinder attainment of
the active conformation of the RAS2 protein without signif-
icantly affecting the GDP bound state. Thus, mutation of
specific residues involved in binding to GEF or residues
important for attainment of the GDP- versus GTP-bound
form could perturb Ras-GEF interactions. Finally, it is also
important to note that mutations in residues that facilitate
the GEF-induced guanine nucleotide exchange may also be
expected to impair Ras-GEF interactions.
A critical role for residues that distinguish the GDP and
GTP versions of Ras may also explain why several domains
have been implicated to be important for Ras-GEF interac-
tions. For example, Stouten et al. (38) recently proposed a
model, which is based on the crystal structures of Ras-GTP
and EF-Tu-GDP, that defines specific residues in helix a2
and loop LS (switch II) (changes in which are propagated to
helix a3 and loop L7) which are important for conversion of
Ras between its active and inactive forms. This may account
for the observation that deletion of residues 103 to 108 in
a3-L7 impairs Ras activation by CDC25 (34). Therefore it is
not entirely surprising that residues identified by different
investigators as being important for GEF interaction are
either surface-accessible residues in helices a2 and a3 (res-
idues 73, 74, 104, and 105) (Fig. 6), whose conformation
differs between GTP- and GDP-bound forms, or residues
(residues 75 to 77) whose flexibility is important for forma-
tion of the active, GTP-bound form. Consequently, GEFs
may interact with several exposed residues present in both
a2 and a3 whose spatial distribution is dependent on the
guanine nucleotide state of Ras.
Biochemical analyses of the specificity of Ras GEF pro-
teins such as CDC25 or SOS suggest that they are specific for
Ras proteins and do not stimulate guanine nucleotide ex-
change on other members of the Ras superfamily (6, 35). As
shown in Table 1, most members of the Ras superfamily
show amino acid divergence in the Ras residues that have
been identified in this study as important for GEF interaction
(39). For example, Rho and Rab protein members show
divergence at all three positions corresponding to Ras resi-
dues 75, 76, and 78. Interestingly, although Ral proteins are
not responsive to Ras GEFs, they share the same residues at
these three positions. Thus, residues flanking positions 75,
76, and 78 may also be important for determining the
specificity of Ras GEFs for Ras proteins. Further mutational
studies of this region in Ras and Ras-related proteins will
help to establish the structural basis for specific stimulation
of Ras by Ras GEFs. Additionally, biochemical and struc-
tural analysis of Ras proteins with mutations at these resi-
dues may help to elucidate the structural basis for the
differential recognition of the GDP- versus GTP-complexed
forms of Ras by GEFs and to determine how GEFs may
trigger the formation of Ras-GTP.
ACKNOWLEDGMENTS
We thank Adrienne Cox for critical comments on the manuscript,
Larry Feig for the Ras(17N) and Ras(17N/186S) cDNA sequences,
Dan Broek for the SOS1 and CDC25 cDNA sequences, and Ronda
Gwynn for assistance in the preparation of the manuscript.
This work was supported by grants from the National Institutes of
Health to C.J.D. (CA42978, CA52072, and CA55008). C.J.D. is the
recipient of an American Cancer Society Faculty Research Award.
ADDENDUM IN PROOF
After submission of this article, mutations at residues 66
and 75 of Ras were reported to perturb its interaction with
SDC25 (L. R. Lowe and C. J. Marshall, Oncogene 8:2583-
2590, 1993).
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